Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of an immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.

Abstract: A rapidly infusing composition that includes a pharmaceutically acceptable binder and/or excipient system containing mammalian gelatin and a sugar alcohol, and at least one supplement selected from the group consisting of a vitamin D compound, vitamin A, vitamin E, vitamin K, vitamin B, vitamin C, and caffeine. Also disclosed is a method of providing nutrient supplementation/modulation and/or a stimulant effect to a subject, whereby the subject in need thereof is administered, via the oral mucosa, the rapidly infusing composition.

Abstract: A method of treating an autoimmune disease and/or inflammatory condition in a subject, whereby the subject in need thereof is administered, via the oral mucosa, a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) a therapeutically effective amount of cannabidiol (CBD) or a derivative/analog thereof. The autoimmune disease and/or inflammatory condition may include, inter alia, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, type-I diabetes, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, and ulcerative colitis, including refractory diseases/conditions thereof.

Abstract: A rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin, sugar alcohol (e.g., mannitol), and a flavorant and (b) an active therapeutic ingredient (ATI). Preferred rapidly infusing compositions are those formulated with a PDE5 inhibitor as the ATI. A method of administering an ATI such as a PDE5 inhibitor to a subject is also disclosed. The subject is administered the rapidly infusing composition via the oral mucosa to treat a condition responsive to inhibition of PDE5, for example, erectile dysfunction.

Abstract: A method of treating autism spectrum disorder (ASD) in a subject, whereby the subject in need thereof is administered, via the oral mucosa, a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) a therapeutically effective amount of cannabidiol (CBD) or a derivative/analog thereof.

Abstract: A container for a lyophilized rapidly infusing composition is described. The container comprises a planar lidding layer attached to a well layer comprising pockets for the therapeutic product. The lidding layer may comprise an aluminum layer, a thermoplastic polymer layer, and a labeling layer. The well layer may comprise an aluminum layer, two polyamide layers, and two thermoplastic polymer layers. A drug product assembly is also disclosed, which includes at least one therapeutic product sealed within the at least one pocket of the container.

Abstract: A method of treating epilepsy in a subject, whereby the subject in need thereof is administered, via the oral mucosa, a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) a therapeutically effective amount of cannabidiol (CBD) or a derivative/analog thereof.

Abstract: A method of treating Tourette syndrome or a tic disorder in a subject, whereby the subject in need thereof is administered, via the oral mucosa, a bioefficient rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) a therapeutically effective amount of cannabidiol (CBD) or a derivative/analog thereof.

Abstract: A method of treating Alzheimer's disease and/or other neurodegenerative disorder in a subject, whereby the subject in need thereof is administered, via the oral mucosa, a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) a therapeutically effective amount of cannabidiol (CBD) or a derivative/analog thereof.

Abstract: A rapidly infusing composition that includes a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and methotrexate. Also provided is a method of treating an autoimmune disease and/or inflammatory condition in a subject, whereby the subject in need thereof is administered, via the oral mucosa, the rapidly infusing composition. The autoimmune disease and/or inflammatory condition may include, inter alia, rheumatoid arthritis, dermatomyositis, psoriasis, systemic lupus erythematosus, eczema, vasculitis, psoriatic arthritis, type-Ii diabetes, multiple sclerosis, Crohn's disease, ulcerative colitis, and sarcoidosis, including refractory/diseases/conditions thereof.

Abstract: A rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) active therapeutic ingredient (ATI). Preferred rapidly infusing compositions are those formulated with tetrahydrocannabinol or a derivative/analog thereof as the ATI. A process for manufacturing the rapidly infusing composition and a method of administering an ATI such as tetrahydrocannabinol or a derivative/analog thereof, to a subject is also disclosed. The subject is administered the rapidly infusing composition via the oral mucosa to activate cannabinoid receptors in the subject, for example to treat conditions such as, inter alia, anorexia, cachexia, nausea, emesis, pain, spasticity, fibromyalgia, overactive bladder, sleep apnea, and/or glaucoma.

Abstract: A rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) active therapeutic ingredient (ATI). Preferred rapidly infusing compositions are those formulated with nicotine or a derivative/analog thereof as the ATI. A method of administering an ATI such as nicotine or a derivative/analog thereof, to a subject is also disclosed. The subject is administered the rapidly infusing composition via the oral mucosa, for example, to reduce the subject's usage of more harmful nicotine delivery methods and/or nicotine withdrawal symptoms.

Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of an immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.

Abstract: A method of treating COVID-19 in a subject, whereby the subject in need thereof is administered, via the oral mucosa, a bioefficient rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) a therapeutically effective amount of cannabidiol (CBD) or a derivative/analog thereof.

Abstract: A composition and method of treatment in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount of an active therapeutic ingredient (ATI). Preferably, a composition and method of treating pain in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount cannabidiol (CBD).

Abstract: A composition and method of treatment in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount of an active therapeutic ingredient (ATI). Preferably, a composition and method of treating pain in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount cannabidiol (CBD).

Abstract: A composition and method of treatment in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount of an active therapeutic ingredient (ATI). Preferably, a composition and method of treating pain in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount cannabidiol (CBD).

Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of an immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.

Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.

Abstract: Veterinary pharmaceutical compositions for direct systemic introduction, also known as DSI pharmaceutical compositions. One veterinary pharmaceutical composition for direct systemic introduction includes about 10-17 dry mass % bovine gelatin; about 10-17 dry mass % mannitol; about 0-1 dry mass % of a surfactant; and about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction includes combining one or more pharmacologically inactive compounds to form a first solution; using one or more surfactants to form a second solution; adding an active pharmaceutical ingredient to the second solution to form a first mixture; adding the first solution to the first mixture to form a pre-formulation; freezing the pre-formulation; and lyophilizing the pre-formulation.